Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate
Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate
Sangamo Therapeutics 2024 年第一季度公认会计准则每股收益 (0.27) 未达到预期 (0.22) 美元，销售额为 481.000 万美元，未达预期 66.54 万美元
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $481.000 thousand which missed the analyst consensus estimate of $6.654 million by 92.77 percent. This is a 99.70 percent decrease over sales of $157.957 million the same period last year.
Sangamo Therapeutics（纳斯达克股票代码：SGMO）公布的季度亏损为每股0.27美元，比分析师普遍预期的0.22美元（0.22美元）低22.73％。与去年同期的每股收益0.12美元相比，下降了325％。该公司公布的季度销售额为48.1万美元，比分析师共识估计的665.4万美元低92.77％。这比去年同期的1.57957亿美元的销售额下降了99.70％。